abstract |
The application provides compounds of formula I and II: and pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2 , R 3 , X, W, Y and Z are as defined in this specification. The application also provides compounds of formulae I and II for use in the treatment of conditions or disorders responsive to inhibition of LSD1, such as cancer. |